Symbols

HOTH

Hoth Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

Significant Net Income Decline

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About HOTH

Hoth Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing the treatment for cancer, anaphylaxis, traumatic brain injury, ischemic stroke, or other neuroinflammatory diseases

Industry

Pharmaceutical

Established Date

05/16/2017

Listing Date

02/15/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.hoththerapeutics.com

Security Type

Common stock

Office address

590 Madison Ave, 21st Floor, New York, New York 10022

Business

Introduction

Hoth Therapeutics, Inc., was incorporated under the laws of the State of Nevada on May 16, 2017. The company is a developing biopharmaceutical company focused on providing targeted therapies for patients with diseases such as atopic dermatitis (also known as eczema). The Company's primary asset is a sub-license agreement with Chelexa, under which Chelexa has granted an exclusive sub-license to use its BioLexa platform, a proprietary, patented, pharmaceutical compound platform developed at the University of Cincinnati. The license allows the development of the platform for any indication in humans. The company's initial focus will be on treating eczema through the application of topical creams. The BioLexa platform combines FDA-approved zinc chelating agents with one or more approved antibiotics in a topical dosage form to address unchecked eczema flares by preventing the formation of infectious biofilms and the resulting blockage of sweat ducts that cause symptoms. The company is the first product candidate designed to prevent symptoms from triggering emergencies rather than simply treating them when they appear.

Company Financials

EPS

HOTH has released its 2025 Q2 earnings. EPS was reported at -0.17, versus the expected -0.27, beating expectations. The chart below visualizes how HOTH has performed over recent quarters, highlighting trends in earnings surprises.